FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma

Retrieved on: 2021-04-09 16:05:06

Tags for this article:

Health sciences

Health

Food and Drug Administration

Medicine

Clinical research

Design of experiments

Clinical trial

Pharmaceutical industry

Glioblastoma

Biologics license application

Alternating electric field therapy

Teprotumumab

Click the tags to see associated articles and topics

FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma. View article details on hiswai:

Excerpt

The corresponding data also produced an activated immune response that correlated with the OS data observed. In the phase 2 trial, 84 patients were ...

Article found on: www.cancernetwork.com

View Original Article